Immunologic and Virologic Outcomes at 6 and 12-months on ART stratified by KS status among 8,676 adult HIV-infected patients initiating ART in Cape Town and Johannesburg, South Africa.

†Models adjusted for sex, baseline CD4 count, age, treatment site, tuberculosis at ART initiation, year of ART initiation.‡VL = viral load, RR = relative risk, CI = confidence interval, relative risk from a log-binomial regression model KS = Kaposi’s sarcoma, ART = antiretroviral therapy,*Failure to achieve a CD4 response defined as an increase of ≥50 cells/mm3 at 6 months and ≥100 cells/mm3 at 12 months.**Failure to suppress VL to†本模型校正了性别、基线CD4计数、年龄、治疗地点、抗逆转录病毒治疗（antiretroviral therapy, ART）启动时合并结核病以及ART启动年份等混杂因素。 ‡病毒载量（viral load, VL）、相对风险（relative risk, RR）、置信区间（confidence interval, CI）；本研究中的相对风险由对数二项回归模型计算得到；卡波西肉瘤（Kaposi’s sarcoma, KS）、抗逆转录病毒治疗（antiretroviral therapy, ART）。 *CD4应答不佳定义为：治疗6个月时CD4细胞计数升高≥50 cells/mm³，且治疗12个月时升高≥100 cells/mm³。 **病毒载量未被抑制至